Acute withdrawal suppression
Usually assessed during or soon after treatment, often within 24–72 hours. It describes short-term withdrawal change, not sustained abstinence.
Plan sheet / outcome definitions
Outcome Guide
“Ibogaine success rate” is not one measurement. This guide separates the outcomes people often combine, the time windows that change their meaning, and the evidence limits that should travel with every number.
Scope note / 2026
Evidence-focused context. Published cohorts, clinic reports, and registered trials are not interchangeable. This page does not make a clinical efficacy claim.
024–72H30–90D6–12M
01 / define the endpoint
One phrase, four distinct outcomes.
Short-term abstinence
Often reported at 30–90 days. Definitions can vary: no use, reduced use, or self-reported abstinence are not the same measure.
Long-term abstinence
Usually concerns 6–12 months or longer. Later results are especially sensitive to follow-up loss, support after treatment, and the definition of return to use.
Symptom reduction
For psychiatric or TBI indications, outcomes may be symptom-scale changes rather than abstinence. These are separate research questions.
Fig. 01 / timing changes the question being answered
02 / evidence map
How to read a reported result.
Published ibogaine studies include observational cohorts, follow-up surveys, clinic-originated reports, case material, and emerging controlled research. These designs can describe what happened in a studied group, but they do not all answer a causal question. The basic distinction between observational research and randomized controlled research matters when interpreting an apparent outcome.
In published cohorts, acute withdrawal relief is commonly the most immediate reported endpoint. Short-term and longer-term outcomes require later contact, and the people who cannot be reached may differ from those who respond. A percentage without the original denominator, response rate, outcome definition, and timing is incomplete.
A result measured at 72 hours can be meaningful as an acute observation. It should not be relabeled as a 12-month recovery rate.
03 / comparison register
Study types answer different questions.
| Evidence type | What it can describe | Common limitation | Outcome window to check |
|---|---|---|---|
| Published cohort study | Outcomes observed in a defined participant group. | Selection, no comparison group, and incomplete follow-up can limit interpretation. | Baseline, acute period, and every later assessment point. |
| Clinic report or survey | Experiences or outcomes reported by people connected to a program. | Definitions, verification, and response rates may be unclear. | Whether the result is immediate, 30–90 days, or 6–12 months. |
| Randomized controlled trial | Comparative outcomes under a defined protocol when one is completed and reported. | Small samples and narrow eligibility can still limit generalization. | Pre-specified primary endpoint and planned follow-up. |
| Registered trial | What researchers intend to test and how outcomes are planned. | Registration is not a completed result and does not establish efficacy. | Listed primary and secondary time frames. |
A trial record can be useful for checking planned endpoints, recruitment status, and measurement windows. The ClinicalTrials.gov study registry distinguishes registered protocols from published findings. For broader context on this site, the plain-language overview of ibogaine outcomes separates early withdrawal observations from longer-term questions.
04 / methods note
A responsible comparison checklist.
- 01Identify the population. Ask which substance-use, psychiatric, or TBI group was studied, and whether participants were selected through a clinic, referral source, or another pathway.
- 02Find the definition of success. Withdrawal score change, self-reported abstinence, toxicology-confirmed abstinence, reduced use, and symptom-scale change are not substitutes for one another.
- 03Locate the measurement window. Separate 24–72-hour outcomes from 30–90-day findings and from 6–12-month follow-up.
- 04Check who was counted. Compare the enrolled group, treated group, assessed group, and number lost to follow-up before comparing percentages.
- 05Look for a comparator. Controlled designs may reduce some sources of bias, while uncontrolled reports require more caution about attribution.
05 / indication boundaries
Do not combine substance-use and symptom outcomes.
For opioid and other substance-use questions, studies may focus on withdrawal, craving, use, abstinence, or treatment engagement. For psychiatric or traumatic brain injury indications, the endpoint may be a symptom inventory, functional measure, or participant report. The National Institute of Neurological Disorders and Stroke overview of traumatic brain injury describes TBI as a distinct health condition; symptom-change reports in that setting should not be presented as addiction abstinence data.
Claims around athletic populations deserve the same endpoint discipline. Discussions involving ibogaine and football, boxing-related ibogaine questions, MMA-focused outcome discussions, or martial arts contexts should specify the studied population, the measure, and the follow-up period rather than imply a shared success rate.
Where a study is observational, it may identify a signal worth studying while leaving important questions open. The standard randomized controlled trial framework helps explain why comparison groups, pre-specified outcomes, and complete follow-up affect confidence in a result.
06 / frequently asked questions
Questions worth asking before accepting a number.
Is there one ibogaine success rate?
No. A reported result depends on what was measured, for whom, and when. Acute withdrawal suppression, short-term abstinence, longer-term abstinence, and psychiatric or TBI symptom change are different endpoints.
Why does follow-up matter?
Follow-up windows and missing responses affect interpretation. A result at 24–72 hours does not establish an outcome at 6–12 months, and loss to follow-up can make later percentages hard to compare.
Are clinic reports the same as controlled studies?
No. Clinic reports can describe experiences in their own populations, but they commonly differ from controlled studies in selection, measurement, verification, and comparison methods.
Where can the broader evidence context be checked?
Blue Arc’s approach to evidence limits and uncertainty explains the standards used for presenting information, while a separate resource on ibogaine beyond Mexico may surface questions about setting and access that should not be confused with an outcome measure.
Review status / cautious interpretation
Inspect trials & timeline
Use the definition before the percentage.
Before relying on a claim, identify the endpoint, time window, study design, and missing follow-up. That is the minimum specification for comparing ibogaine outcome reports responsibly.